Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback